SignalChem Lifesciences Corporation

October 09, 2014 09:00 ET

SignalChem Lifesciences Opens Chemistry Laboratory

Added Resources Build on Expertise and Reduce Drug Development Life Cycle as Company Continues Significant Development of Its Kinase Programs

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 9, 2014) - SignalChem Lifesciences Corporation ("SLC" or the "Company"), developers of a world-class kinase technology platform that is generating new, patient-specific, drug candidates for the targeted treatment of cancer and other diseases, announced today the launch of its new chemistry laboratory.

The new chemistry laboratory provides much needed medicinal and computation chemistry in support of the Company's four lead oncology targets: AXL, TYRO3, MELK and IRAK4. Managed by Harvard and Cambridge trained chemists having worked at globally recognized organizations such as Amgen and Jubilant, the SLC chemistry laboratory is well positioned to help expedite these oncology programs through to pre-clinical development in early to mid-2015.

The laboratory is a wholly owned subsidiary, located in Bangalore India, and currently employs 25 full-time chemists. The Company expects to double the laboratory's capacity by the close of 2014 to further drive SLC's drug development life cycle.

"This is a momentous occasion for our company," emphasizes Jasbinder Sanghera. "In addition to our biology expertise and a platform of over 470 available kinase targets, this significant chemistry resource now securely positions SLC as a leading player in the kinase drug discovery and development space. With 40 chemists working on our projects by the end of 2014, we will continue to build the first-in-class and best-in-class patient-specific kinase drug candidates for our Oncology, Inflammation/Autoimmune and CNS programs."

"In a short period of time, the Company has delivered a number of exciting initiatives," remarked SLC's newest board member and investor Darrell Oswald, formerly of Phillips, Hager & North. "Establishing this lab provides the Company another vital pathway to control costs, improve access to quality chemistry and reduce the typically long drug development cycle-time facing many other companies today."

About SLC

SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases. The Company has a robust Kinase Platform encompassing 470 kinase targets and assays for the development and commercialization of unique therapies for many diseases. This vast resource empowers SLC's scientists to identify novel drug candidates against kinase targets of interest. Another key part of SLC's kinase drug development platform is KineCore™, a kinase focused small molecule library that was designed and assembled in-house. For more information, refer to the Company's website at www.signalchemlifesciences.com.

About Kinase Inhibitors

Defects in kinases account for numerous medical conditions including cancer, inflammation and neurological diseases. Kinase inhibitors account for one of the fastest growing market segments in the therapeutic market place. Since the first kinase inhibitor Imatinib was approved by FDA in 2001, 26 kinase inhibitors have been approved for the treatment of cancers and RA. In total, including upfront fees, milestones and royalty structures, kinase deals in excess of $15bn have been completed in the last 8 years alone.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact Information